98%
921
2 minutes
20
An animal model of radiation-induced lung injury (RILI) was established using female rats given sublethal whole-thorax X-ray irradiation (15 Gy) at a dose rate of 2.7 Gy/min. The rats were studied for up to day 45 and compared with sham-irradiated controls. Time-series lung tissue samples during the progression of RILI were collected for dynamic metabolomics studies based on gas chromatography-mass spectrometry (GC-MS). Differential metabolites associated with radiation-induced lung injury were identified, followed by metabolite set enrichment analysis to uncover pathway changes in RILI. The results revealed dynamic metabolic alterations in the progression of RILI, primarily involving in glycine and serine metabolism, the urea cycle, the Warburg effect, glutamate metabolism, arginine and proline metabolism, glucose-alanine cycle, and ammonia recycling. In addition, the potential panel of biomarkers including taurine, lysine, and tyrosine of RILI was selected and then applied to evaluate the diagnostic potential for RILI based on the receiving operator characteristic curve (ROC) at the early-stage of RILI. The better sensitivity, specificity, and accuracy indicate the potential of early diagnosis for RILI. These findings suggest that dynamic metabolomics data could provide new insights into understanding the complex metabolic dysregulation underlying RILI, facilitating the selection of biomarkers for early diagnosis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bmc.6061 | DOI Listing |
BMC Cancer
September 2025
Department of Oncology, School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Background: Radiotherapy (RT) remains a cornerstone in the treatment of thoracic malignancies; however, approximately one-third of patients with non-small cell lung cancer (NSCLC) develop Grade ≥ 2 radiation-induced lung injury (RILI). Despite its clinical significance, no pharmacologic standard of care has been established for RILI. Pirfenidone, an antifibrotic agent with anti-inflammatory and antioxidant properties, has demonstrated potential in preclinical models of RILI.
View Article and Find Full Text PDFMol Carcinog
August 2025
Department of Cancer Center, Army Medical Center of PLA, Chongqing, China.
Radiation-induced lung injury (RILI) is a prevalent complication of thoracic tumor radiotherapy, severely compromising treatment efficacy and the patients' quality of life, yet effective prevention or treatment strategies remain elusive. Folic acid (FA), a water-soluble vitamin, plays critical roles in DNA synthesis/repair, cell cycle regulation, epigenetic regulation via methylation, oxidative stress response, and embryonic development. However, its radioprotective role has not been systematically elucidated.
View Article and Find Full Text PDFClin Lung Cancer
July 2025
Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
Radiation-induced lung injury (RILI) remains a significant complication of thoracic radiotherapy, with clinical presentations ranging from asymptomatic radiological changes to life-threatening pneumonitis and long-term fibrosis. Given the increasing use of thoracic irradiation and the growing complexity of combined modality treatments, including immunotherapy, a multidisciplinary and standardized approach to the clinical management of RILI is essential. This article presents expert recommendations jointly developed by the French Society of Radiation Oncology (SFRO) and the French Association for Supportive Care in Oncology (AFSOS), with the aim of guiding clinicians in the diagnosis, grading, and supportive management of RILI.
View Article and Find Full Text PDFEur J Pharmacol
August 2025
Jilin Provincial Key Laboratory of Radiation Oncology & Therapy, Department of Radiation Oncology & Therapy, The First Hospital of Jilin University, Changchun, 130021, China; NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, 130021, China. Electronic address:
Radiation-induced lung injury (RILI) remains a significant complication of thoracic radiotherapy, with radiation-induced pulmonary fibrosis (RIPF) representing a serious and irreversible outcome. Epithelial-mesenchymal transition (EMT) has emerged as a critical contributor to RIPF progression; however, the underlying mechanisms remain poorly understood. Captopril (Cap), an angiotensin-converting enzyme inhibitor with established cardiovascular benefits, has been demonstrated to show protective effects against RILI.
View Article and Find Full Text PDFRadiat Res
August 2025
Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania.
Radiation-induced lung injury (RILI) includes early acute phase radiation pneumonitis (RP), and late chronic phase radiation-induced pulmonary fibrosis (RIPF). There is increasing evidence that ionizing radiation-induced cellular senescence is associated with pulmonary fibrosis. We have recently reported that biomarkers of senescence and, specifically, tyrosine kinase Fgr are induced in mouse RIPF, human idiopathic pulmonary fibrosis (IPF), and in human RIPF.
View Article and Find Full Text PDF